Human Malaria (5-Plex) ELISA Kit

Malaria is a serious parasitic disease caused by Plasmodium species, transmitted primarily through the bites of infected female Anopheles mosquitoes. It poses a significant global public health challenge, particularly in regions such as Africa, Asia, and Latin America. According to the World Health Organization (WHO), approximately 219 million people were infected with malaria in 2017, resulting in 435,000 deaths, with the majority of fatalities occurring among children in sub-Saharan Africa. The disease' s burden remains disproportionately heavy in these tropical regions despite ongoing efforts to control its spread. There are five primary species of Plasmodium that infect humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, and Plasmodium knowlesi. Of these, P. falciparum is responsible for the most severe cases and accounts for the majority of malaria-related deaths globally. P. vivax is also widely spread but is less deadly, though it often leads to recurrent infections due to its ability to remain dormant in the liver for extended periods before reactivating. In Southeast Asia, P. knowlesi, a zoonotic parasite, has become an emerging concern due to its ability to jump from animals to humans. Malaria's life cycle is complex and involves both human and mosquito hosts. When an infected mosquito bites a person, it injects Plasmodium sporozoites into the bloodstream. These sporozoites quickly travel to the liver, where they infect liver cells and begin replicating. After a period of replication, the parasites are released back into the bloodstream as merozoites, where they invade red blood cells. Inside these cells, they multiply and eventually cause the cells to burst, releasing more parasites into the bloodstream. This cyclic process is what triggers the classic symptoms of malaria, including high fever, chills, and anemia. The timing of these symptoms typically ranges from 7 to 30 days after infection, depending on the species of Plasmodium. Severe cases, particularly those caused by P. falciparum, can escalate rapidly and, if untreated, may lead to life-threatening complications such as cerebral malaria, acute respiratory distress syndrome (ARDS), or kidney failure

Figure 1. Lifecycle of Plasmodium falciparum (Source: Cowman AF, et al., 2016)

Historically, malaria has been documented for thousands of years. Ancient Chinese texts, including the Huangdi Neijing (The Yellow Emperor's Classic of Medicine), described symptoms similar to malaria as far back as 2700 BCE. The Ebers Papyrus from ancient Egypt, dated to around 1550 BCE, also contains references to symptoms consistent with malaria. In the 4th century BCE, the Greek physician Hippocrates observed that people living in marshy areas were more prone to febrile illnesses, associating malaria with the "bad air" of swamps—a belief that persisted for centuries. It was not until 1880 that French physician Alphonse Laveran discovered the Plasmodium parasite in the blood of malaria patients, earning him the Nobel Prize in Medicine in 1907. His work laid the foundation for understanding the parasitic nature of malaria and its transmission through mosquitoes. Malaria continues to be a major source of morbidity and mortality despite international attempts to stop its spread, especially in sub-Saharan Africa, which accounts for more than 90% of the disease's worldwide impact. The most common species in this area, Plasmodium falciparum, is the cause of severe and frequently fatal disease manifestations. Malaria is a serious public health risk in places with limited healthcare resources because it primarily affects children under five. The emergence of drug-resistant malaria strains in recent decades has made managing and treating the illness more difficult. Chloroquine was the first-line treatment for malaria in the middle of the 20th century, but resistance to the medication quickly developed, especially in regions with high transmission rates. Today, artemisinin-based combination therapies (ACTs) are the standard treatment for P. falciparum malaria. However, resistance to artemisinin has already been detected in parts of Southeast Asia, raising concerns about the future effectiveness of this vital drug class. As drug resistance continues to spread, the development of new antimalarial drugs is an urgent priority for researchers.

In terms of prevention, insecticide-treated bed nets (ITNs) and indoor residual spraying (IRS) have been among the most effective tools in reducing malaria transmission by controlling mosquito populations. These measures have significantly reduced malaria cases in some regions. In 2021, the World Health Organization approved the first malaria vaccine, RTS, S/AS01, for widespread use. This vaccine targets P. falciparum and has shown promise in protecting young children in sub-Saharan Africa. However, its efficacy is limited, and further research is needed to develop more potent vaccines capable of providing long-lasting protection. In addition to vaccines and drugs, scientific advancements in gene editing have opened new avenues for malaria control. One such innovation is the gene drive technology, which could potentially alter mosquito populations by introducing genetic changes that make them less capable of transmitting Plasmodium. This technology aims to reduce malaria transmission at the source by genetically modifying mosquitoes. While promising, gene drive technology faces significant ethical and environmental challenges, including concerns about unintended ecological consequences and the long-term sustainability of such interventions. The fight against malaria is far from over, but continued progress in drug development, vaccine research, and genetic technologies offers hope for better control and eventual elimination of the disease. As the global health community works towards reducing malaria's burden, efforts remain focused on overcoming drug resistance, improving prevention strategies, and developing innovative approaches to tackle this ancient yet persistent disease. With sustained investment and collaboration, malaria eradication may one day become a reality.

Plasmodium antigen ELISA kit
Malaria antigen detection kit
Plasmodium detection ELISA
Malaria diagnostic ELISA kit